0001104659-20-037012.txt : 20200320
0001104659-20-037012.hdr.sgml : 20200320
20200320213036
ACCESSION NUMBER: 0001104659-20-037012
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200316
FILED AS OF DATE: 20200320
DATE AS OF CHANGE: 20200320
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gionco David
CENTRAL INDEX KEY: 0001456864
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35619
FILM NUMBER: 20733418
MAIL ADDRESS:
STREET 1: 9 HOWELL DRIVE
CITY: FAR HILLS
STATE: NJ
ZIP: 07931
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: STEMLINE THERAPEUTICS INC
CENTRAL INDEX KEY: 0001264587
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 450522567
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 750 LEXINGTON AVENUE
STREET 2: ELEVENTH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: 646-502-2311
MAIL ADDRESS:
STREET 1: 750 LEXINGTON AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10022
4
1
a4.xml
4
X0306
4
2020-03-16
0
0001264587
STEMLINE THERAPEUTICS INC
STML
0001456864
Gionco David
C/O STEMLINE THERAPEUTICS, INC.
750 LEXINGTON AVENUE, ELEVENTH FLOOR
NEW YORK
NY
10022
0
1
0
0
Chief Accounting Officer
Common Stock
2020-03-16
4
S
0
2849
3.88
D
316885
D
In connection with the vesting of 5,000 shares on March 15, 2020, a total of 2,849 shares were sold by the Company on March 16, 2020 in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies.
Reflects the weighted average sale price. The range of prices for the shares sold on March 16, 2020 was $3.62 to $4.05. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies.
Of the shares listed, 237,741 shares are restricted stock.
/s/ David Gionco
2020-03-20